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Abstract
A substantial fraction of broadly neutralizing antibodies (bnAbs) in certain HIV-infected donors
recognizes glycan-dependent epitopes on HIV-1 gp120. Here, we elucidate how bnAb PGT 135
recognizes its Asn332 glycan-dependent epitope from its crystal structure with gp120, CD4 and
Fab 17b at 3.1 Å resolution. PGT 135 interacts with glycans at Asn332, Asn392 and Asn386,
using long CDR loops H1 and H3 to penetrate the glycan shield to access the gp120 protein
surface. Electron microscopy reveals PGT 135 can accommodate the conformational and chemical
diversity of gp120 glycans by altering its angle of engagement. The combined structural studies of
PGT 135, PGT 128 and 2G12 show this Asn332-dependent epitope is highly accessible and much
more extensive than initially appreciated, allowing for multiple binding modes and varied angles
of approach, thereby representing a supersite of vulnerability for antibody neutralization.
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The human immune system initially generates strain-specific neutralizing antibodies to
HIV-1 that recognize only a fraction of the massively diverse mutational variants of its
envelope glycoprotein (Env)1. In the infected host, the virus diversifies extensively and
escapes from these narrowly focused antibodies. Strong selection pressure drives variation
in its exposed surfaces, including its five hypervariable loops (V1-V5) and around 27 N-
linked glycans that cover most of the gp120 envelope glycoprotein surface2-4. Despite this
extraordinary sequence variation and “evolving glycan shield”, broadly neutralizing activity
is found in 5-25% of donor sera after 2-3 years of infection5,6. However, by this time, the
virus has firmly established itself, overwhelming even broadly neutralizing responses.
Nevertheless, elicitation of such responses by a vaccine prior to virus exposure may lead to
prophylactic protection against HIV-1.
Given that neutralizing antibody selection pressure shifts glycosylation sites on the virus
during the course of infection2, it is reasonable to assume that these antibodies may not only
be targeting protein surfaces near glycans, but also the glycans themselves. This notion is
supported by observations of serum neutralizing activity that is dependent on the presence of
the glycan attached to Asn3327-10 and by the recent discovery of several broadly
neutralizing antibodies (bnAb) that interact with gp120 in a glycan-dependent manner. Four
antibodies isolated from different HIV-1 infected donors and derived from different
germline families, PGT 12111, 2G1212, PGT 12813 and PG914, have been structurally
characterized in complex with individual glycans, a gp120 outer domain fragment, and a
scaffolded glycopeptide, respectively. A number of other glycan-dependent bnAbs,
including PG16 and PGT 121-123, 130-131 and 142-145 (n.b. the PGT antibodies are
grouped according to their predicted shared germline precursor), await structural
characterization in complex with Env15,16.
To further elucidate the bnAb target around Asn332, we conducted structural and functional
analysis of PGT 135, an Asn332 (N332) glycan-dependent bnAb isolated from an individual
whose serum has one of the highest neutralization breadths known16,17. The PGT 135
epitope includes three glycans and protein segments that differs substantially from other
Asn332-dependent epitopes and enables PGT 135 accommodation of HIV-1 Env glycan
heterogeneity through some variation its angle of approach to the gp120 surface. Hence, the
Asn332-dependent epitope constitutes a major site of vulnerability on the glycosylated face
of gp120 that can be accessed by antibodies from different germline precursors using
completely different modes of recognition and, most likely, different mechanisms of
neutralization.
Results
Structural characterization of PGT 135 binding to gp120
To elucidate the interaction with gp120, we tested PGT 135 Fab complexed with a number
of gp120 constructs and additional ligands for crystallization. The additional ligands
included soluble CD4 receptor and Fabs recognizing gp120 to increase the chances of
crystallization18. Crystals of a quaternary complex (i.e. four protein components) consisting
of PGT 135 Fab, JR-FL core gp120, CD4 D1D2 and 17b Fab (Fig. 1) diffracted to 3.1 Å
resolution (Table 1), while unliganded Fab135 crystals diffracted to 1.75 Å (Table 1). The
JR-FL gp120 monomeric core bound to PGT 135 Fab with high affinity [82 nM by ITC
(Supplementary Table 1)], but the corresponding virus was only weakly neutralized by PGT
135 IgG unless specific mutations were introduced into the V1-V2 loops, which are >25 Å
away from the epitope in the monomeric gp120 structure and probably affect binding
indirectly by impacting trimer interactions (Fig. 2)19. Nevertheless, the weak neutralization
that we observed correlates with an approximate μM binding affinity for the Env trimer. A
number of bnAb-Env complexes in this affinity range have been structurally elucidated, e.g.
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b12 with a stabilized gp120 core construct20 and PG9 with V1-V2 loop scaffolds14 and
these structures are consistent with many published findings on Env biology.
The crystal structure shows that CD4, 17b and PGT 135 are bound to gp120 in nearly
orthogonal orientations (Fig. 1a). After partially deglycosylating the gp120/PGT 135
complex by endoglycosidase H (EndoH) prior to crystallization, we observed only single N-
acetylglucosamine (GlcNAc) moieties in the gp120 electron density at Asn339, Asn362,
Asn448, Asn262 and Asn276, whereas high mannose (Man) glycans interacting with PGT
135 were protected and we observed density for GlcNAc2Man at Asn386 (N386),
GlcNAc2Man6 at Asn332 and GlcNAc2Man8 at Asn392 (N392). When compared to its
unliganded structure, PGT 135 does not undergo any large conformational changes [0.4 Å
Cα root-mean-square deviation (RMSD) between Fab variable domains] (Supplementary
Fig. 1a-b). The gp120 structure is also highly similar in both the PGT 135-CD4-17b-
gp120JRFL and the CD4-17b-gp120HXBC complexes20 (0.5 Å Cα RMSD), suggesting that
PGT 135 does not induce any further conformational changes when it binds to gp120. This
inference was corroborated by ITC data: the ΔG, ΔH and TΔS values for PGT 135 binding to
unliganded gp120 and to the gp120-CD4 complex were nearly equivalent (Supplementary
Table 1). Therefore, evidence that PGT 135 neutralizes virus by inducing conformational
changes in gp120 or by direct inhibition of CD4 binding is lacking. However, the PGT135
neutralization mechanism still remains unclear although we note that the PGT 135 epitope
also involves residues from the V4 loop. In another study, an anti-FLAG antibody, which
neutralizes recombinant virus containing a FLAG insert in the V4 loop21, appears to
function via nonspecific steric coverage of the virion22 instead of blocking functionally
important surfaces such as the CD4 binding site.
PGT 135 engages gp120 primarily via a long 18-residue CDR H3 loop, which has 10 amino-
acid insertions after position 100 (n.b. the average human CDR H3 is 13 residues using the
Kabat definition of H95-H10223), and an extended CDR H1 loop containing a rare 5 amino-
acid insertion not present in the predicted germline sequence (Supplementary Fig. 2); both
CDR loops protrude approximately 20 Å from the VH surface, comparable to the length of
high mannose N-linked glycans. The VH CDR loops in unliganded PGT 135 converge to
form a highly hydrophobic horseshoe-shaped surface consisting of Trp34 from CDR H1,
Trp53 from H2, and Val100-FMLVP-Ile100F from H3 (Supplementary Fig. 1d). A salt
bridge between Arg54 on the tip of H2 and Glu33 near the top of the H1 loop insertion helps
hold these loops in place. These features remain intact after binding to gp120
(Supplementary Fig. 1c).
PGT 135 buries a complex epitope consisting of 438 Å2 of protein and 1010 Å2 of glycan
surface on gp120 (Fig. 1 and Supplementary Table 2), which is larger than the typical
antibody footprint (～700-900 Å2). 83 percent of the protein-protein buried surface involves
side chains on gp120 (Supplementary Table 2) in contrast to PG9 and PGT 128 that rely
primarily on backbone interactions with V1-V2 and V3, respectively, to form main-chain β-
strand associations13,14. The CDR H1 and H3 tips primarily contact gp120 β-strand 19,
which connects the V4 loop to β-strand 20, as part of the bridging sheet (Fig. 1b), and
adjacent β-strand 13, between V3 and α-helix 2, where His330 is particularly important for
binding and neutralization (Supplementary Table 2-3). On the gp120 V4 loop, Glu409
interacts with CDRs L2 and H3, forming a protein-protein interaction zone that is
discontinuous from the rest of the contacts. The CDR H1 insertion allows access to the
protein surface around the Asn386 glycan (GlcNAc2Man), which separates the PGT 135
epitope from the CD4 binding site. Trp34 on the tip of the CDR H1 insertion interacts with
the Asn386 glycan. Coincidentally, bnAb b12 also contacts residues near the Asn386 glycan
via CDR H3 Trp100, which occupies a similar position to PGT 135 H1 Trp3420. Deletion of
the H1 insertion significantly reduced PGT 135 binding and neutralization of different
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HIV-1 isolates (Fig. 2b-c), suggesting that this extended loop is important for the antibody-
antigen interaction.
The large glycan binding surface of PGT 135 is created by the CDR loops draping
themselves across the entire length of the N-linked glycans at Asn392 (547 Å2) and Asn332
(365 Å2), where multiple van der Waals interactions and hydrogen bonds are made from the
mannose sugars at the tips to the GlcNAc moieties at the stem (Fig. 1, Fig. 3 and
Supplementary Table 2, 4-7). The Asn386 glycan interaction is significantly less (99 Å2,
two van der Waals interactions with H1) than with the Asn392 and Asn332 glycans, but
nonetheless critical for neutralization of various HIV-1 strains (Fig. 3d), (Supplementary
Tables 3-7). Interestingly, the Asn392 and Asn332 glycans interact with opposite faces of
PGT 135 CDR H3 in a bifurcated manner reminiscent of bnAb PG9 and PGT 128 binding to
dual glycans on epitope-scaffolded V1-V2 loops (PG9) or gp120 outer domain (PGT 128),
respectively (Fig. 3a). However, unlike these other bnAbs, whose interacting glycans are on
adjacent β-strands, the two glycans interacting with PGT 135 CDR H3 are on independent β-
strands separated by β-strand 19 (Fig. 1). VL also contacts the Asn332 glycan via CDR L3
on one side of VL, whereas CDR L2, and VL framework regions 2-3 on the opposite side
interact with the Asn392 glycan (Fig. 1).
Glycan specificity of PGT 135
N-linked glycans exhibit multiple levels of heterogeneity, arising from variable positioning
of the glycosylation sequons on gp120, differential processing by Golgi enzymes, and
conformational flexibility24,25. To understand how PGT 135 achieves relatively broad
neutralizing activity despite dependence on heterogeneous glycans, we employed virus
neutralization and binding assays based on virus and gp120s from different strains with
various N-linked glycosylation knockouts, along with glycan arrays and different expression
systems (Fig. 3b-d). These results were compared with analysis of the glycans in the crystal
structure of a partially deglycosylated PGT 135 complex. Crystallization required partial
deglycosylation of the complex, which we carried out with the rationale that EndoH will
preferentially cleave the more exposed and flexible N-linked glycans26 that are not protected
by PGT 135 binding (Supplementary Fig. 3d).
Pseudoviruses prepared from mammalian 293T cells (complex, hybrid and oligomannose
glycans) or 293S cells (Man5-9GlcNAc2 oligomannose glycans) had similar PGT 135
neutralization profiles (Fig. 3c). These results are consistent with the crystal structure, which
shows interaction only with an oligomannose glycan patch on gp12027 that would be present
when gp120 is expressed in either cell line, and validate the use of 293S cells to produce the
gp120 for the crystal study. In contrast to 2G12 and PGT 128, PGT 135 also neutralized
pseudoviruses from cells treated with N-butyldeoxynojirimycin (NB-DNJ), which results in
either missing or glucosylated (i.e. masked) D1 arms of N-linked glycans28. This
observation is also consistent with the crystal structure because PGT 135 does not interact
with the Asn332 glycan D1 arm and only with the second mannose residue of the Asn392
glycan D1 arm, which would not be affected by NB-DNJ treatment (Fig. 3a). Also in
contrast to 2G12 and PGT 128, adding kifunensine to the expression system, which limits
glycan processing to Man9GlcNAc2, resulted in loss of neutralization by PGT 135. Again,
the crystal structure is compatible with this outcome: modeling an additional mannose
residue to the D2 arm of the Man8 glycan at Asn392 would result in a severe steric clash
(Supplementary Fig. 3a). The D2 arm of the Man6 glycan at Asn332 is also sterically
crowded, but may be able to accommodate a terminal mannose with some slight adjustment
(Supplementary Fig. 3b). In contrast, the D3 arm of the Asn332 glycan is free from any
steric clash with the antibody (Supplementary Fig. 3c).
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Glycan array binding assays showed that PGT 135 recognized Man7-9 glycans exclusively
and bound to these with lower affinity than 2G12 and PGT128 (Fig. 3b). Although PGT 135
appears to bury extended glycan moieties in the binding site, most of the contacts are van
der Waals interactions and the antibody makes only 4 hydrogen bonds to the Asn332 glycan.
In contrast, PGT 128, which generated a substantially higher glycan binding signal on
glycan arrays, makes 13 hydrogen bonds with the Asn332 glycan. The pattern of binding to
these glycans is dependent on the density, clustering and conformation of the presented
glycans; in a different glycan array format using non-covalently immobilized N-linked
glycans as neoglycolipids that have an element of mobility, only Man8 and Man7 glycans
without the terminal D2 mannose were recognized (Supplementary Table 8). The array
analyses and kifunensine effect described above can be reconciled if binding to glycans
other than Asn392, most likely Asn332, can occur via Man8 or Man9. While a homogenous
display of glycans on an array is unlikely to mimic the actual presentation of the glycans on
gp120, use of multiple arrays containing different coupling chemistries and printing
densities allows more opportunity to assess the glycan specificity of PGT 135.
Virus neutralization and binding assays revealed differential effects of these N-linked
glycosylation sites on PGT 135 activity against different isolates of HIV-1 (Fig. 3d). Not
surprisingly, Asn332 and Asn392 were required for all isolates tested because most of the
antibody contacts are to these glycans. However, the requirement for Asn295 (N295) and
Asn386 glycans, as well as His330 residue, on gp120, was strain dependent. Although the
Asn295 glycan does not contact PGT 135 in the context of the JR-FL core gp120, these data
suggest it may be recruited by the antibody in the context of other HIV-1 strains so that the
epitope would be modified and strain-dependent. Thus, although the PGT 135 interaction is
highly specific for particular glycoforms on gp120, it may also be promiscuous by
exploiting a neighboring Asn295 glycan for recognition of some HIV-1 strains. By targeting
the oligomannose patch on gp120 where the required glycoforms are present, while
tolerating a certain range of alternate glycan positions, PGT 135 may acquire broad
neutralizing breadth despite the heterogeneity seen in the Env glycan populations. Overall,
the data point towards two general requirements for PGT 135 binding, with the caveat that
any given isolate may deviate from the most common pattern of recognition: 1) high
mannose glycans within the context of the tightly clustered high mannose patch on gp120
and 2) a D2 arm on the glycan at Asn392 lacking at least the terminal mannose residue.
Structural explanation for neutralization breadth of PGT 135
PGT 135 can neutralize 33% of HIV-1 isolates at an IC50 <50 ug ml−1 using a 162 cross-
clade virus panel, which is comparable to bnAb b12 (34%), but less than PGT 128 (72%)7,
although PGT 135 and 128 both recognize epitopes critically dependent upon the same
highly conserved Asn332 glycan7. The variability of important residues and glycan sites was
examined using 3045 aligned gp120 sequences (Los Alamos HIV Database). The sequence
conservation of the essential elements necessary for gp120 binding agrees well with
neutralization breadth (Supplementary Table 2). For PGT 128, glycans at Asn332 (73%
conserved) and Asn301 (N301) (92% conserved) are critical for neutralization; both glycan
motifs are present together in 69% of the sequences, which is close to the observed 72%
neutralization breadth7. For PGT 135, glycans at Asn332, Asn392, Asn295, Asn386, and
His330 (73%, 79%, 59%, 87%, and 71% conserved, respectively) are all important for
neutralization (Supplementary Table 2). His330, Asn332 and Asn392 are all required for
neutralization of all isolates tested (Fig. 3d) and these three sites are found concurrently in
50% of the sequences. However, PGT 135 recognition also requires Asn295 and Asn386
glycans in a strain-dependent manner. His330, glycans at Asn332, Asn392, and either
Asn295 or Asn386 are found in 31% or 42% of the sequences, while His330 along with all
four glycan motifs (332, 392, 295, and 386) is present in 26% of the sequences. The
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observed neutralization breadth of PGT 135 is 33% of test isolates7, suggesting that the
dispensability of either Asn295 or the Asn386 glycans in certain strains enhances
neutralization breadth compared to a requirement for all four glycans.
PGT 135 interaction with gp120 trimer
We used electron microscopy (EM) to characterize PGT 135 Fab binding to a glycosylated
clade A BG505 SOSIP.664 gp140 trimer29. Three Fabs were bound per trimer, with the
gp120 protomers in a more closed conformation (Fig. 4a) than the more open conformation
seen with CD4 binding site ligands30. The PGT 135 angle of approach to the gp120 epitope
avoids any clash with neighboring gp120 protomers or interference with the CD4 binding
site (Fig. 4a). The 2D class averages showed that PGT 135 occupies a distinct epitope from
PGT 128, which also recognizes the Asn332 glycan (Fig. 4b), but we observed significant
variance in the orientation of Fab PGT 135 relative to the trimer (Fig. 4c, Supplementary
Movie 1). Principal component analysis (PCA) of the variance clearly illustrated some
flexibility in the Fab PGT 135 interaction with the trimer compared to PGT 128 (Fig. 4d,
Supplementary Movie 2). This increased variance for PGT 135 may represent a distribution
of different angles of approach due to some slight shift between the interacting glycans or
with the glycoforms it contacts (Fig. 4d). The use of alternative angles of approach may
therefore reflect an immunologic countermeasure to some natural variation in the N-linked
glycans that decorate the Env surfaces of different HIV-1 isolates.
Discussion
Recent advances in our understanding of immune responses against HIV-1 Env have
revealed that extremely potent, broadly neutralizing responses can be made against the
glycosylated face of gp120, particularly around the Asn332 glycan. PGT 135, 2G12 and
PGT 128 bnAbs are all dependent on the Asn332 glycan but have distinct binding motifs
and quite different angles of approach, and yet their neutralization activity is not
compromised (Fig. 5a). This scenario contrasts with antibodies whose binding footprints
overlap the CD4 binding site where small differences in angle and relative position result in
clashes with neighboring gp120s31 and very different extents of neutralization from VRC01
(bnAb, 93% breadth) to F105 (non-neutralizing)5. Thus, these Asn332-dependent antibodies
define a novel and unexpectedly broad supersite for neutralization (Fig. 5b), which
encompasses 6 conserved glycans and the underlying protein surface.
Overall in comparing HIV-1 bnAbs that interact with glycans, PGT 135 is similar to PGT
128 and PG9 in its use of heavy chain CDR loops to penetrate through the glycan canopy to
contact the underlying protein surface with PG9 uniquely using a hammerhead-shaped CDR
H3 loop for the interaction. As with PGT 128, but not PG9, PGT 135 also relies on a second
extended CDR loop on the heavy chain (H1 in PGT 135 and H2 in PGT 128) to contact
antigen. Despite different amino-acid lengths, these extended CDR loops are at similar
distances from the antibody (15-20 Å), reflecting the length of an N-linked glycan from the
underlying protein surface. In contrast, 2G12 only contacts the outermost mannose residues
of the interacting glycans, a feature that presumably results from its unusual VH domain-
swap to attain high affinity binding.
In terms of the relative glycan positioning within the binding sites, we also observe some
similarities. For Fabs PGT 135, PGT 128 and 2G12, the distances between the two major
interacting glycans on the gp120 surface (measured between the asparagine-bound carbons
of the protein proximal GlcNAcs of the glycans) are remarkably similar at around 18-20 Å.
The PG9 glycans are also spaced similarly at 15 Å. These similarities in distances likely
reflect constraints imposed by the dimensions of the Fab interacting surfaces, the
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requirement that a CDR loop penetrate between glycans, and the density of the glycans on
the gp120 surface.
Although three different bnAbs recognize the same Asn332 glycan, they contact chemically
distinct surrounding surfaces. 2G12 binds to the glycan tips and is, therefore, highly
dependent on the presence of the terminal mannose residues in a particular linkage. In
contrast, PGT 135 and PGT 128 recognize the complete length of the glycan at Asn332, but
approach from and interact with different sides of the glycan. Strikingly, the glycan
conformation and orientation is largely unchanged in the PGT 135 and PGT 128 structures
(Fig. 6a), despite the known conformational flexibility of glycans. This conformational
stability confers the carbohydrate with two chemically distinct “faces” at the level of the
entire glycan; a much more flexible glycan would not have such well-defined faces because
its overall orientation and conformation would be rapidly changing. The Asn332 glycan
faces are defined by the sum of the contributions from the apolar and polar faces of
individual sugar rings that then determine the net polarity of the complete face. The sugar
hydroxyl groups extend from the polar side of a sugar ring, thereby potentially mediating
more hydrophilic-type interactions compared to the apolar face (Fig. 6b). Thus, some ‘rules’
for interaction with individual sugars have been established whereby aromatic residues, such
as Trp, typically stack on the apolar face of sugars and hydrophilic and charged residues
interact with the polar face and hydrogen bond with the ring hydroxyl groups32.
We observed that PGT 135 interacts predominantly with an apolar face consisting of three
individual apolar sugar ring faces and one polar sugar ring face (Fig. 6c) with 61% of the
buried surface in the interaction mediated by the individual apolar faces. PGT 128 interacts
with a predominantly polar face consisting of 5 individual polar sugar faces and 2 individual
apolar sugar ring faces, with 58% of the buried surface mediated by the polar faces (Fig. 6d).
Conversely, PGT 135 residues interacting with the apolar face of glycan 332 are
predominantly hydrophobic (～64% of the buried surface area contacts are mediated by
apolar residues), while PGT 128 residues are about equally hydrophobic and hydrophilic
(～54% of the buried surface in the interaction are mediated by apolar residues. It should be
noted that the apolar interactions, particularly ring stacking, would naturally involve much
greater surface area than hydrophilic interactions. Similarly, PGT 128 interactions with the
polar face of glycan 332, involve many more hydrogen bonds compared to PGT 135 (13
versus 4). Thus, we conclude that the different faces of the Asn332 glycan are an important
determinant for antibody recognition of this supersite.
The discovery of bnAbs in a SHIV-infected macaque that depend on the Asn332 glycan, in
addition to those described above in infected humans7-9, raises the prospect that suitable
immunogens that display these combined glycan and protein epitopes in an appropriate
configuration can be tested as vaccine candidates in animal models for re-elicitation of
similar glycan-dependent antibodies. Furthermore, a recent study showed that broadly
neutralizing responses were raised against the Asn332 glycan in two human individuals
initially infected with a virus initially lacking the Asn332 glycan, but which contained an
Asn334 glycan that is present only when Asn332 is absent9. The Asn332 glycan emerges
later in the infection, but the virus can revert back to the Asn334 glycan, resulting in escape
from the immune response. Although most viruses have the Asn332 glycan (73%) rather
than the Asn334 glycan (20% conserved), a vaccine may need to be capable of inducing
responses to either glycan site.
It is still not clear why the Asn332 glycan is so dominant among antibodies targeting this
supersite, but one possibility is that it is not only highly conserved (73%) and predominantly
oligomannose, but also conformationally restrained by adjacent sugars. Indeed, the glycan
Asn332 conformation is nearly identical in the crystal structures of PGT 12813 and PGT 135
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(Fig. 6), suggesting that the immune system is presented with a comparatively well-ordered
glycan shield, at least for glycan Asn332. Heterogeneity of surrounding glycans may be
accommodated, as suggested by the distribution of angles of approach utilized by PGT 135,
and in the case of PGT 121 potentially being able to bind both high mannose and complex
glycans11. One implication for vaccine design is that immunization with an antigen
containing a heterogeneous mix of glycoforms and glycosylation sites may promote
“promiscuous” antibodies that have greater neutralization breadth. However, this benefit
may be countered by a dampened immune response, in which case different vaccination
schedules and adjuvants would need to be tested. Ultimately, to mimic this supersite using
rational vaccine design, such as epitope scaffolding33,34, to create vaccine immunogens, one
should carefully consider how to reconstitute a faithful representation of the glycan canopy
with glycoforms that are similar to those in the intact Env trimer.
Online Methods
Expression and purification of PGT 135 and 17b Fab
PGT 135 Fab was expressed using a baculovirus system with SF9 cells as described
previously in ref. 13. PGT 135 was purified from the cell supernatant first by anti-human
lambda affinity chromatography followed by cation exchange chromatography and size
exclusion chromatography using Superdex 200™ (GE Healthcare) as previously
described13. Fab 17b was obtained from digesting IgG 17b with papain using a previously
described protocol from ref. 12.
Expression and purification of JRFL gp120 core
A JRFL gp120 core containing a short (mini) V3 region (residues 305-320 deleted and
replaced by a proline residue as described in ref. 13) was cloned into a phCMV3 vector with
an IgK secretion signal. This plasmid was used to transfect HEK 293S GnT1-/- (293S) cells
using 293Fectin (Invitrogen) under serum free conditions. The protein was purified first
through a Galanthus nivalis lectin column, followed by SEC with Superdex 200™ (GE
Healthcare).
Expression and purification of BG505 SOSIP.664 trimer
The HIV-1 clade A BG505 Env sequence and the construction of SOSIP.664 trimers35 using
the Env sequence of BG505.W6M.ENV.C2 (GenBank Accession ABA61516/DQ208458)
designed with a T332N mutation36 is described in ref. 29. The BG505 SOSIP.664 trimer
was expressed and purified as previously described in ref. 13. The BG505 SOSIP.664 trimer
was purified using a 2G12-coupled affinity matrix followed by passage through a sizing
column.
Crystallization and data collection
Unliganded PGT 135 Fab crystallized over a period of 28 days at 20 °C in a crystallization
reagent consisting of 20% (w/v) PEG 8000, 0.1 M CHES, pH 9.5. Crystals were harvested
and cryoprotected by a brief immersion in 70% well buffer, 30% glycerol, followed by
immediate flash-cooling in liquid nitrogen. Data were collected at APS beamline 23ID-B
(wavelength: 1.033 Å) at 100 K. Data were processed and scaled with HKL-200037.
Quaternary complexes of PGT 135 crystallized in 20% PEG 2000, 0.1 M Tris pH 7.0 (JCSG
CoreSuite I Well C07) using our automated CrystalMation robotic system (Rigaku). An
optimization screen was made around this condition and large single crystals were obtained
from 16% w/v PEG MME 2000, Tris pH 7.87 using the Oryx8 Crystallization robot. Data
were collected at the ALS beamline 5.0.2 (wavelength: 1.000 Å) at 100 K, and were
processed and scaled with HKL-200037. All data processing statistics are summarized in
Table 1.
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Structure determination and refinement
The unliganded PGT 135 structure was determined by the molecular replacement method
using Phaser with an unrelated Fab structure (PDB ID: 3KYM) as an initial model. For the
quaternary complex, multiple components were used for phasing: 17b Fab (PDB ID:
2NXY), soluble CD4 (PDB ID: 2NXY), gp120 core (PDB ID: 2NXY) and high-resolution
unliganded PGT 135 Fab as determined here. Model building was carried out using
Coot-0.6.2 and refinement was implemented with the Phenix program38. See Supplementary
Note for refinement details and Table 1 for final refinement statistics.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) binding experiments were performed using a
MicroCal iTC200 instrument (GE). See Supplementary Note for details.
gp120 binding ELISAs
Recombinant gp120 (250 ng) was immobilised directly onto flat bottom microtitre plates
(Costar type 3690, Corning Inc.) at 4°C overnight. Antibody binding was determined as
described above. Fold change in binding for PGT 135 mutants is summarized in
Supplementary Table 9.
Generation of pseudovirus
Pseudovirus was generated in HEK 293T or GnT1-/- deficient 293S cells as described
previously39. Glycosidase inhibitors were added at the time of transfection and were used
alone or in combination at the following concentrations as described in ref. 13: 25 μM
kifunensine and 2 mM N-butyldeoxynojirimycin (NB-DNJ).
Neutralization assays
Neutralization activity of antibodies against pseudovirus in TZM-bl cells was determined as
described previously39. Fold change in neutralization for PGT 135 mutants is summarized in
Supplementary Table 10
Antibody and envelope mutations
Mutations in the PGT heavy chain, the HIV-1envelope glycoprotein and the JRFLmV3
construct were introduced using QuikChange site-directed mutagenesis (Stratagene, La
Jolla, CA). Mutations were verified by DNA sequencing (Eton Biosciences, La Jolla, CA).
JR-FLmV3 glycan mutant binding ELISAs
JR-FLmV3 glycan mutants were expressed in 293S cells. Glycoproteins from the crude
supernatant were captured onto ELISA plates using mAb 17b. Serial dilutions of
biotinylated PGT 135 were added and antibody binding was probed with alkaline
phosphatase conjugated streptavidin (Jackson, diluted to 1:1000) and visualized with p-
nitrophenol phosphate substrate (Sigma) at 405 nm.
High density high-mannose array printing
Man7GlcNAc2-Gly, Man8GlcNAc2-Gly, and Man9GlcNAc2Gly were printed in replicates
of six onto NHS-activated glass slides (from ADA Technologies, Inc) at a concentration of
100 μM as previously described in ref. 13 using a MicroGridII contact microarray printing
robot. Printing efficiency was determined by measuring ConA binding.
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Binding of antibodies to high-density high-mannose array
Binding of PGT 135, PGT128 and 2G12 antibodies was measured at 30 μg/mL and detected
using goat-anti-human-Fcγ-R-PE (15 μg/mL, Jackson). Arrays were scanned for R-PE
fluorescence on a ProScanArray HT (PerkinElmer) confocal slide scanner at 70PMT90LP.
Signal intensities were collected using Imagene (BioDiscovery) image analysis software and
calculated using the mean intensity of 4 replicate spotted samples.
Comparison of PGT 135 binding to low density (Schott slides) and high-density (ADA
slides) glycan microarrays
Glycan microarray analysis was initially carried out on high-mannose glycans printed on
NHS-activated slides obtained from Schott as in ref. 13, but binding of PGT 135 could not
be detected (Supplementary Fig. 5a). However, PGT 135 glycan binding could be detected
(Supplementary Fig. 5a) using the glycan array imprinted on higher density NHS-activated
slides from ADA Technologies, Inc. As a comparison, we show that binding of PGT128 was
greatly enhanced using the high-density slides (Supplementary Fig. 5b) and strong binding
on the array could still be detected at 1μg/mL.
Neoglycolipid (NGL) microarray analyses
Analysis with neoglycolipid arrays was carried out as described previously in ref. 13. PGT
135 was pre-complexed with biotinylated anti-human-IgG (Vector) at a 1:3 ratio, w/w,
before applying onto the slides at a final concentration of 10 μg/ml. Binding was detected
with Alexa-Fluor 647 labeled streptavidin (Molecular Probes) at 1 μg/ml. Included for
comparison are the results with human 2G12 (Polymun Scientific) taken from an earlier
experiment performed using a different version of microarrays40, PGT128 and plant lectin
ConA in ref. 13 (Supplementary Table 8; Supplementary Fig. 5c)
Electron microscopy and image processing
PGT 135 Fab in complex with the BG505 SOSIP.664 trimer used for electron microscopy
studies were prepared as previously described in ref. 13. Particles were picked automatically
using DoG Picker and put into a particle stack using the Appion software package41,42.
Initial reference-free 2D class averages were calculated using particles binned by 4 via the
Xmipp Clustering 2D Alignment43, and IMAGIC software programs44. Particles were
further classified into reference-free 2D class averages and refined using Refine2d in the
EMAN package45 (Supplementary Fig. 6a). An ab initio 3D model was generated by
refining the EM map of an unliganded BG505 SOSIP.664 trimer for 29 iterations, against
the 2D class averages from the last Refine2d iterations. This initial model was used for the
final 75-iteration 3D refinement against 8,831 raw particles binned by 2 using EMAN45. C3
symmetry was imposed throughout the reconstruction process. The final 3D reconstruction
has a resolution of 20 Å by an FSC cut-off at 0.5 (Supplementary Fig. 6b).
Fitting of gp120/PGT 135 crystal structure into the EM density
Due to the high B-values in the constant region of the PGT 135 Fab, initial rigid body fitting
of the crystal structure was done with only the gp120 and the variable region of the PGT 135
Fab (Supplementary Fig. 6c). This structure was manually fit into the EM density and
refined using the UCSF Chimera ‘Fit in Map’ function. The crystal structure with the full
Fab was then aligned to the fitted structure using the ‘Match’ command. The fitting of
trimeric gp120-PGT 135 crystal structure was further refined using the ‘Fit in Map’ function
resulting in a final correlation value of 0.91.
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Analysis of Fab binding degeneracy
Candidate top views of PGT 135-trimer and PGT128-trimer particles were subjected to two
rounds of reference-free 2D class averaging using Xmipp Clustering 2D Alignment43. 2D
class averages with the clearest top views of gp120 were selected from the PGT 135 and
PGT128 alignments to be used as a template for the respective datasets. A circular mask was
applied to conceal the Fabs, and the remaining particles from the second round of reference
free 2D alignments were re-classified via IMAGIC Multi Reference Alignment, and
IMAGIC Multivariate Statistical Analysis programs44. The 164 and 160 aligned particles for
PGT 135 and PGT128 respectively, from best the 2D class average for each were selected
for 2D principal component analysis (PCA). The PCA analysis was carried out through the
Sparx package46 using the first 5 eigenvectors. UCSF Chimera was used to create morph
movies (Supplementary movies 1-2) between the average image and each of the
eigenvectors to visualize the flexibility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Crystal structure of PGT 135 in complex with HIV-1 gp120
(a) The glycan-dependent interaction between PGT 135 and gp120 is presented in ribbon
representation in the context of the gp120 ternary complex that contains a 2-domain CD4
and the Fab of CD4-induced antibody 17b. An enlarged display of the PGT 135-gp120
interaction is shown to the lower right. The CDR H1 and H3 loops (blue and red
respectively) penetrate deeply through the glycan canopy to contact protein surface below
while the light chain contacts the glycans using CDR loops and framework regions. (b)
Buried surface on gp120 protein surface and attached glycans N332, N386 and N392 by
CDR loops and framework regions of PGT 135. The values are in Å2.
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Figure 2. PGT 135 neutralization and binding
(a) Neutralization activity of PGT 135 and 2G12 were assayed against JR-FL pseudovirus in
TZM-bl cells. Neutralization of WT JR-FL and of JR-FL containing V1-V2 loop mutations
E168K and N188A are shown. (b) Binding of PGT 135 IgG mutants to gp120 from various
strains (JRCSF, JRFL) as well as JRFLmV3 were measured by ELISA. Mutations include
deletion of the CDR H1 insert “EWGDK”, alanine substitution of the CDR H2 arginine that
supports the CDR H1 insert with a salt bridge, and mutation of VFMLV to AAMAA in
CDR H3. Wild-type PGT 135 and 2G12 IgGs are included as controls. (c) Neutralization
potency of PGT 135 mutant IgGs against JRCSF, SF162 and 92RW020. Error bars represent
the standard deviation. Experiments were performed in duplicate and repeated three times.
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Figure 3. Glycan dependency of PGT 135 binding to gp120
(a) PGT 135 interactions with gp120 glycans. The 2Fo-Fc electron density (contoured at 1σ)
of N392, N332 and N386 glycans are shown along with contacting residues on PGT 135. A
schematic of each glycan is shown beside the structures for the sugars that are visible in the
electron density with GlcNAc as dark blue squares and mannose residues as green circles.
The surface area (Å2) on each glycan moiety buried by PGT 135 is shown. (b) Interactions
of PGT 135, PGT 128 and 2G12 with oligomannose glycans on a high-density microarray.
The error bars represent standard deviations where n=6. (c) Glycan dependency of PGT 135
neutralization using BaL pseudoviruses produced in different cell systems. Virus produced
in 293T cells contains complex, hybrid and oligomannose type glycans, whereas in 293S
cells only Man5-9GlcNAc2 glycans are present. Addition of kifunensine yields only
Man9GlcNAc2 glycans. NB-DNJ blocks the glycan processing at neutral glucosylated
glycans. Error bars represent the standard deviation. Each experiment was performed in
duplicate and repeated at least three times. (d) The effect on PGT 135 neutralization from
single mutations removing glycans and His330 for several HIV-1 strains. Values are
presented as fold change in IC50 of variant envelope compared to WT envelope (fold change
= IC50 variant/IC50 WT). Boxes are color coded for fold change; red: >100, orange 10-100,
yellow 4-9 and green <4. n.d.: not determined. a values were determined by ELISA instead
of neutralization.
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Figure 4. A gp140 trimer binds Fab PGT 135 in slightly different orientations in contrast to
PGT128, which is bound in a single orientation
(a) The PGT 135-gp120 structure is shown fitted into the EM density map of PGT 135 in
complex with the BG505 SOSIP.664 gp140 trimer in top and side views of the trimer. (b)
2D difference map of the two 2D class averages. The PGT128-SOSIP class average was
subtracted from the PGT 135-SOSIP class average. The overlap is shown as the black gap in
the trimer region. (c) Top view of the 2D class averages of the BG505 SOSIP.664 gp140
trimer in complex with PGT 135 (left) and PGT128 (right). The images contributing to the
class averages were aligned using a top view back projection of an undecorated gp140
SOSIP.664 trimer. On the top, the Fabs are colored cyan and yellow for PGT 135 and
PGT128, respectively. Below are variance maps of the trimer in complex with PGT 135
(left) and PGT128 (right) indicating the variability in the images that went into the 2D class
averages. Brighter pixel values correspond to a greater degree of variability in that region.
(d) An overlay of the 2D class average (blue outline) and the first eigenvector (orange) of
the 2D PCA analysis for PGT 135 and PGT128.
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Figure 5. Supersite of vulnerability centered on the N332 glycan
(a) Binding to the N332 glycan on gp120 for PGT 135, 2G12 and PGT 128 is shown with
their respective structures superimposed on glycan N332. (b) The epitopes of PGT 135, PGT
128 and 2G12 are shown in topology representations in which cylinders are α-helices,
arrows are β-strands and lines are loops. N-linked glycan sites are circled. The structures of
2G12 (PDBID: 1OP5) and PGT 128 (PDBID: 3TYG) were obtained from the PDB.
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Figure 6. Conserved conformation of N332 glycan
(a) The N-linked glycan at N332 of gp120 has a conserved conformation in crystal
structures with PGT 135 (blue) and PGT 128 (light brown). The structures are superposed
on the gp120 protein. (b) Definition of A and B faces of a glycan residue. The B face
(labeled in red), on which the carbons are arranged counter-clockwise around the ring, is
generally more apolar than the A face (labeled in cyan), on which the carbons are arranged
clockwise around the ring. (c,d) The side from which each glycan moiety interacts with PGT
135 (c) or PGT 128 (d) is defined by an arrow pointing towards the interaction (red arrow
indicates B face, cyan arrow indicates A face and grey arrow indicates the side of a glycan).
Each sugar primarily uses its A face, B face, or the side in the interaction with the different
antibodies; their buried surface areas are estimated based on the burial on each glycan
residue. The structure of PGT 128 (PDBID: 3TYG) is available from the PDB.
Kong et al. Page 20

























Kong et al. Page 21
Table 1
Data collection and refinement statistics (molecular replacement)
PGT 135 PGT 135-gp120-CD4-17b
Data collection
Space group P21212 C2
Cell dimensions
 a, b, c (Å) 85.89, 138.15, 42.34 218.41, 92.15, 88.19
 α, β, γ (°) 90.00, 90.00, 90.00 90.00, 104.75, 90.00
Resolution (Å) 31.4-1.75 43.58-3.10
(1.78-1.75)a,b (3.20-3.10)a,b
Rsym 0.06 (0.47) 0.06 (0.60)
I/σI 27.6 (1.9) 16.9 (1.72)
Completeness (%) 96.1 (73.8) 99.7 (98.8)
Redundancy 6.5 (4.0) 3.7 (3.3)
Refinement
Resolution (Å) 31.40-2.75 43.58-3.10
No. reflections 49,464 30,850
Rwork/Rfree 20.7/24.5 24.6/36.7
No. atoms
 Protein 3475 10,560
 Glycan/Ligand/ion 347
 Water 273 1
B factors
 All proteins 41 127
 gp120 117
 17b Fab 129
 CD4 D1D2 149
 PGT135 con c 43 151
 PGT135 var c 39 99
 Glycans 112
 Ligands 109
 Water 46 76
r.m.s. deviations
 Bond lengths (Å) 0.006 0.012
 Bond angles (°) 1.11 1.46
aOne crystal for each structure was used for data collection and structure determination.
bValues in parentheses are for highest-resolution shell.
c
For PGT 135 Fab, average B-values for the constant (con) and variable (var) domains were calculated.
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